Trial · NCT00070499
Results by group328
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 328
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Molecular Response Rate at 12 Months | Standard Dose Imatinib A | 5 | participants | ||
| Molecular Response Rate at 12 Months | High Dose Imatinib | 14 | participants | ||
| Molecular Response Rate at 12 Months | Dasatinib | 27 | participants | ||
| Molecular Response Rate at 12 Months | Standard Dose Imatinib B | 18 | participants | ||
| Hematologic Response | Standard Dose Imatinib A | 63 | participants | ||
| Hematologic Response | High Dose Imatinib | 66 | participants | ||
| Hematologic Response | Dasatinib | 107 | participants | ||
| Hematologic Response | Standard Dose Imatinib B | 112 | participants | ||
| 2-year Overall Survival (OS) | Standard Dose Imatinib A | 89 | Percent of population | ||
| 2-year Overall Survival (OS) | High Dose Imatinib | 95 | Percent of population | ||
| 2-year Overall Survival (OS) | Dasatinib | 97 | Percent of population | ||
| 2-year Overall Survival (OS) | Standard Dose Imatinib B | 98 | Percent of population | ||
| Two Year Relapse-free Survival | Standard Dose Imatinib A | 83 | Percent of population | ||
| Two Year Relapse-free Survival | High Dose Imatinib | 97 | Percent of population | ||
| Two Year Relapse-free Survival | Dasatinib | 96 | Percent of population | ||
| Two Year Relapse-free Survival | Standard Dose Imatinib B | 95 | Percent of population | ||
| Toxicity | Standard Dose Imatinib A | ALT, SGPT (serum glutamic pyruvic transaminase) | 1 | Participants with a given type of AE | |
| Toxicity | High Dose Imatinib | ALT, SGPT (serum glutamic pyruvic transaminase) | 3 | Participants with a given type of AE | |
| Toxicity | Dasatinib | ALT, SGPT (serum glutamic pyruvic transaminase) | 1 | Participants with a given type of AE | |
| Toxicity | Standard Dose Imatinib B | ALT, SGPT (serum glutamic pyruvic transaminase) | 3 | Participants with a given type of AE |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00070499/results